ReviewCurrent atherosclerosis reports2019
Current Role of Lipoprotein Apheresis.
Review in Current atherosclerosis reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- The Impact of Lipoprotein apheresis on Plasma Protein Levels: A Meta-Analysis.Journal of clinical apheresis · 2026Pooled it
- Apolipoprotein E Mimetic Peptide-Mediated Modulation of Lipid Homeostasis.Biomolecules · 2026Review
- Toward an Integrated Therapeutic Approach for Familial Hypercholesterolemia.Current medical science · 2026Review
- Lipoprotein(a) in cardiovascular disease: pathophysiology, residual risk, and emerging therapeutic strategies.Frontiers in medicine · 2026Review
- Indications and recent evidence for apheresis in children and adults with kidney diseases: a comprehensive review.Clinical kidney journal · 2025Review
- Liver Transplantation in a Child With Homozygous Familial Hypercholesterolemia: A Case Report and Literature Review.Reviews in cardiovascular medicine · 2025Review
- Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.The Lancet. Child & adolescent health · 2024Article
- Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?International journal of molecular sciences · 2024Review
- Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.Atherosclerosis plus · 2024Review
- Bibliometric analysis of residual cardiovascular risk: trends and frontiers.Journal of health, population, and nutrition · 2023Article
- Treatment of Lp(a): Is It the Future or Are We Ready Today?Current atherosclerosis reports · 2023Review
- Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a).Current atherosclerosis reports · 2023Review
- Genetic Testing for Familial Hypercholesterolemia in a Pediatric Group: A Romanian Showcase.Diagnostics (Basel, Switzerland) · 2023Article
- Review
- Apheresis: What Should a Clinician Know?Current atherosclerosis reports · 2023Review
- Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.Signal transduction and targeted therapy · 2022Review
- The Role of Endothelial Progenitor Cells in Atherosclerosis and Impact of Anti-Lipemic Treatments on Endothelial Repair.International journal of molecular sciences · 2022Review
- Editorial: Highlights in Lipids in Cardiovascular Disease: 2021.Frontiers in cardiovascular medicine · 2022Article
- An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.Frontiers in medicine · 2022Review
- Familial Hypercholesterolemia: Global Burden and Approaches.Current cardiology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewLipoprotein apheresis is a very efficient but time-consuming and expensive method of lowering levels of low-density lipoprotein cholesterol, lipoprotein(a)) and other apoB containing lipoproteins, including triglyceride-rich lipoproteins. First introduced almost 45 years ago, it has long been a therapy of "last resort" for dyslipidaemias that cannot otherwise be managed. In recent years new, very potent lipid-lowering drugs have been developed and the purpose of this review is to define the role of lipoprotein apheresis in the current setting. RECENT
findingsLipoprotein apheresis still plays an important role in managing patients with homozygous FH and some patients with other forms of hypercholesterolaemia and cardiovascular disease. In particular, patients not achieving treatment goals despite modern lipid-lowering drugs, either because these are not tolerated or the response is insufficient. Recently, lipoprotein(a) has emerged as an important cardiovascular risk factor and lipoprotein apheresis has been used to decrease lipoprotein(a) concentrations in patients with marked elevations and cardiovascular disease. However, there is considerable heterogeneity concerning the recommendations by scientific bodies as to which patient groups should be treated with lipoprotein apheresis. Lipoprotein apheresis remains an important tool for the management of patients with severe drug-resistant dyslipidaemias, especially those with homozygous FH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.